Albireo Pharma, Inc.
|Number of Estimates|
Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.
Market Cap: 305 Million
Primary Exchange: NASDAQ
Shares Outstanding: 12.7 Million
Float: 10.2 Million
Sector: Health Technology
Industry: Pharmaceuticals: Other
Longest drawdown: 2156 trading days
From: 2013-08-02 To: 2020-01-22
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|